2023年5月5日

新闻分享这篇文章提供的洛杉矶,CA,美国,5月5日2023 / EINPresswire.com——圣洛克治疗提出的行动违反联邦RICO(联邦诈骗和腐败组织行为),欺骗性的诱因和不公平的商业行为在美国马萨诸塞地区法院对被告尼克•Leschly米切尔细,菲利普·赖利,第三摇滚事业,蓝鸟生物Inc .和2七十生物Inc .尼克Leschly第三摇滚企业一些最大的收入者制药行业在过去的十年。尼克Leschly由24000000年的2018美元,主要是通过出售股份的知更鸟在生物。Leschly先生是世界上最高补偿制药公司首席执行官。被告的行为损害每个纳税人当然,代价是病人。圣洛克疗法(SRT)是一种生物技术/生物制药公司和全球领先的基因治疗的研究。SRT提起72页RICO投诉星期四,2023年4月27日。这RICO申请源于11月2日,2020年纽约最高法院解决蓝鸟生物之间,第三摇滚事业和SRT。结算/证实了SRT的专有权决定基因治疗专利,蓝鸟生物侵犯。制药公司高管的不当行为导致了成千上万的病人死亡。最近,司法部解决与萨克的家人和普渡大学医药帮助创建了阿片类药物的滥用流行。 Richard Sackler was the CEO. In 2012, the Justice Department levied a 3 billion dollar fine against GlaxoSmithKline for treacherous behavior used during the clinical trials of the antidepressant Paxil. Thousands of adolescents committed suicide. The CEO during the clinical trial process of Paxil was Jan Leschly. SRT believes that it has a safer gene therapy product that will cost over $2,000,000 less per patient. Recent published data indicates that insulators will make gene therapy vectors safer. SRT hopes that its court actions will result in accessible, safe therapy for patient There are over 100,000 Sickle Cell Disease patients in the US, a disease that predominantly affects the African American population. Thus, Leschly’s crimes considerably affect ethnic communities. Click here for the publicly filed complaint Case 1:23-cv-10919